Singapore Institute of Advanced Medicine Holdings Ltd. (SGX:9G2)
Singapore
· Delayed Price · Currency is SGD 0.0360
0.00 (0.00%)
At close: Mar 6, 2026
SGXC:9G2 Income Statement
Financials in millions SGD. Fiscal year is July - June.
Millions SGD. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 | Jun '21 Jun 30, 2021 |
| Revenue | 15.93 | 15.71 | 16.65 | 16.23 | 13.81 | 12.92 |
| Revenue Growth (YoY) | -1.27% | -5.63% | 2.54% | 17.56% | 6.90% | - |
| Cost of Revenue | 8.76 | 8.94 | 7.83 | 6.37 | 5.17 | 4.88 |
| Gross Profit | 7.17 | 6.77 | 8.82 | 9.87 | 8.64 | 8.04 |
| Selling, General & Admin | 10.6 | 11.4 | 11.47 | 11.95 | 11.56 | 8.86 |
| Amortization of Goodwill & Intangibles | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0 |
| Other Operating Expenses | 4.97 | 5.13 | 5.62 | 5.97 | 5.14 | 2.7 |
| Operating Expenses | 27.12 | 28.48 | 29.55 | 23.69 | 21.95 | 16.7 |
| Operating Income | -19.94 | -21.7 | -20.73 | -13.83 | -13.32 | -8.66 |
| Interest Expense | -3.37 | -2.91 | -11.22 | -2.25 | -1.03 | -1.03 |
| Interest & Investment Income | 0.03 | 0.03 | 0.04 | 0.03 | 0.02 | 0.03 |
| Currency Exchange Gain (Loss) | 0.02 | 0.02 | -0.01 | 0.02 | -0.43 | 0.44 |
| Other Non Operating Income (Expenses) | -0.09 | -0.11 | -7.28 | -3 | -0.16 | -0.16 |
| EBT Excluding Unusual Items | -23.36 | -24.68 | -39.2 | -19.03 | -14.92 | -9.39 |
| Gain (Loss) on Sale of Assets | - | - | 0.01 | -0 | 0.44 | - |
| Asset Writedown | -2.47 | -2.47 | - | - | - | - |
| Other Unusual Items | -0.2 | 0.1 | 1.75 | 0.06 | - | - |
| Pretax Income | -26.03 | -27.05 | -37.44 | -18.96 | -14.48 | -9.39 |
| Earnings From Continuing Operations | -26.03 | -27.05 | -37.44 | -18.96 | -14.48 | -9.39 |
| Earnings From Discontinued Operations | -0.01 | -0.01 | -0.01 | 0.89 | 2.05 | 0.04 |
| Net Income | -26.03 | -27.05 | -37.45 | -18.07 | -12.43 | -9.35 |
| Net Income to Common | -26.03 | -27.05 | -37.45 | -18.07 | -12.43 | -9.35 |
| Shares Outstanding (Basic) | 1,144 | 1,052 | 823 | 679 | 645 | 533 |
| Shares Outstanding (Diluted) | 1,144 | 1,052 | 823 | 679 | 645 | 533 |
| Shares Change (YoY) | 13.70% | 27.90% | 21.15% | 5.25% | 21.04% | - |
| EPS (Basic) | -0.02 | -0.03 | -0.05 | -0.03 | -0.02 | -0.02 |
| EPS (Diluted) | -0.02 | -0.03 | -0.05 | -0.03 | -0.02 | -0.02 |
| Free Cash Flow | -4.63 | -10.8 | -13.46 | -17.68 | -9.89 | -7.87 |
| Free Cash Flow Per Share | -0.00 | -0.01 | -0.02 | -0.03 | -0.01 | -0.01 |
| Gross Margin | 45.02% | 43.11% | 52.99% | 60.78% | 62.54% | 62.22% |
| Operating Margin | -125.19% | -138.15% | -124.56% | -85.17% | -96.43% | -67.06% |
| Profit Margin | -163.40% | -172.22% | -224.95% | -111.32% | -89.98% | -72.38% |
| Free Cash Flow Margin | -29.05% | -68.74% | -80.88% | -108.89% | -71.66% | -60.94% |
| EBITDA | -11.37 | -12.72 | -11.19 | -10.99 | -11.01 | -6.62 |
| EBITDA Margin | -71.37% | -81.00% | -67.25% | -67.71% | -79.74% | -51.28% |
| D&A For EBITDA | 8.57 | 8.98 | 9.54 | 2.83 | 2.31 | 2.04 |
| EBIT | -19.94 | -21.7 | -20.73 | -13.83 | -13.32 | -8.66 |
| EBIT Margin | -125.19% | -138.15% | -124.56% | -85.17% | -96.43% | -67.06% |
| Advertising Expenses | - | 0.25 | 0.29 | 0.23 | - | - |
Source: S&P Capital IQ. Standard template. Financial Sources.